Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of Recombinant Malaria Vaccines (LYB014, LYB017, LYB027) in Healthy Adults
NCT07831226Phase 1Not yet recruiting
- Sponsor
- Patronus Biotech
- Start
- Oct 2026
- Primary completion
- Apr 2028
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LYB014, LYB017 and LYB027 in malaria (7 arms), sponsored by Patronus Biotech. Primary endpoints: Immediate adverse events, Solicited local and systemic adverse events at 7 days and 3 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
LYB014LYB017LYB027
03
Conditions
malaria
Beyond the preview
Go deeper on NCT07831226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07831226.